Category: Diagnostics
The point of care diagnostics and testing market has climbed dramatically with the rise of the Covid-19 public health crisis. We’re seeking applications for diagnostics startups who would like to take part in INVEST Pitch Perfect Diagnostics 2.0 track at the conference, scheduled to take place March 28-30 in Chicago.
It turns out that the laws governing traditional Medicare don’t provide for coverage of self-administered diagnostic tests. Medicare patients are left to seek free tests other ways, including through the administration’s new website, covidtests.gov, and at community centers.
The deal between Stamford, Connecticut-based Sema4 and GeneDx’s parent, Miami-based OPKO Health, was fortified with a $200 million private placement from growth and life sciences investors, including Pfizer.
A month after Freenome closed $300 million in financing, Roche has invested another $290 million in the diagnostics developer. The cash infusion comes as Freenome continues a pivotal test in colorectal cancer while it also readies for clinical trials in other types of cancer.
The deadline to apply to the MedCity INVEST Pitch Perfect contest in Chicago, scheduled for March 28-30 at the Ritz Carlton, is January 31.
To improve heart attack prevention, there is an urgent unmet need to modernize our approach from late-stage symptom-driven care to direct disease-based care, a care paradigm that addresses heart attack risk in all patients across the entire continuum of heart disease severity.
Elizabeth Holmes, the founder and former chief executive of the blood testing startup Theranos, has been convicted of defrauding investors by a jury in a California court and is facing a prison sentence. Prosecutors claimed that Holmes (37) knowingly misled shareholders in Theranos with the promise that the company’s technology could diagnose a battery of […]
Performance-based risk sharing (PBRS) have grown in importance in recent years. While most PBRS are used for expensive pharmaceutical products, PBRS also have been used with medical device and diagnostic manufacturers. Device/diagnostic PBRS may differ from those of pharmaceuticals for a number of reasons. First, while health insurers bear the burden of paying for most […]
What draws investors to healthcare startups? In this series in the runup to MedCity INVEST in Chicago, we’ll highlight these perspectives. If you’re a startup in pharma tech, value-based care and care coordination, diagnostics or remote patient monitoring/smart devices, apply to our Pitch Perfect contest today.
The Covid-19 pandemic has brought a laser focus to the critical and immediate need for next-generation sequencing tools that can generate invaluable data for not only identifying emerging variants but for understanding the functional and epidemiological consequences of variant-specific mutations.
Welsh medtech company Bond Digital health has raised £1 million ($1.3 million) in additional funding for its data capture and management system for lateral flow tests (LFTs). The Cardiff-based company said it will use the new money to expand its headcount, including hiring a new customer service team, and adding to its sales, marketing and […]
Genetic tests are becoming available for a wider range of applications. During a CB Insights panel discussion, Phil Febbo of Illumina and Alicia Zhou of Color explained what they think needs to happen to make these tests accessible and affordable for more people.
The Toronto-based startup is applying AI to ultrasound signals. It differentiates healthy tissue from diseased tissue by measuring its acoustic properties.
INVEST, scheduled for March 28-30, 2022 in Chicago, marks a return to in-person events for MedCity News. The conference, held in partnership with Mid-America Healthcare Investors Network, will spotlight healthcare innovation, investment trends, and share insights from healthcare executives.
Recognized as Method of the Year by Nature in 2020, spatial transcriptomics employs advanced imaging methods with novel chemistry techniques that stand to dramatically expand our understanding of health and disease.
General Electric plans to spin out its healthcare business into a publicly traded entity in 2023. It’s part of a broader restructuring as the company looks to turn around its business.
The company expanded a recall of its at-home Covid-19 tests due to a manufacturing error. The FDA upped the recall to a Class 1 recall, its most serious level, after noting a higher-than-acceptable false positive rate for the affected tests.
During these uncertain times, remember to proactively reach out to patients and encourage them to resume routine cancer screenings to prevent delayed diagnoses that might lead to worsened health outcomes
The UK government has announced £248 million in spending over the next year for a project to make it easier for patient test results and scans to be shared between hospitals, labs and GP surgeries. The aim is to “digitise diagnostics care” across the NHS, reducing the time it takes to diagnose health problems and […]
Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics in response to emailed questions from MedCity News.
New semiquantitative tests offer a more granular understanding of our protective immunity, not only identifying Covid-19 antibodies but providing direct, individualized measures of neutralizing antibody levels.
The Menlo Park-based company is building a service for quick at-home health services, such as lab draws and Covid-19 testing. The company is looking to build the “DoorDash for lab draws,” raising $33 million from backers.
Utilizing POC testing for sepsis is a pragmatic solution for risk-stratification of new patients, helping physicians to prioritize those for treatment based on the severity of their condition.
A new service from MedCity News is designed to add momentum to lead generation campaigns.
The Food and Drug Administration granted an emergency use authorization for an at-home Covid-19 and flu test kit by Labcorp. It uses a test that was developed by Roche and authorized last year.
Diagnostics startup GRIP Molecular is developing an at-home test for Covid-19 and other respiratory infections. The technology builds on advances from several fields, including the discovery of graphene, a material that offers biocompatibility and conductivity.
A study published by Verily researchers showed that some smartphone metrics, such as sentiment in weekly voice diaries, matched up with the severity of users’ depression as determined by PHQ-9 scores. Even if these technologies could be used to track mental health, it’s not clear how they will fit into physician workflows or how comfortable […]
The diagnostics company opened on the Nasdaq on Friday, trading for $20 per share. It’s now trading at $18.63 per share.
An NHS study of a new cancer blood test holds huge promise, but will not be without its challenges, says Snedden Campbell’s Ivor Campbell. The announcement that the NHS is taking part in a major new clinical trial for a blood test that could detect more than 50 cancers early has been welcomed as a […]
The call to action is that point-of-care testing needs to move to the home and it needs to be supported by a Medicaid or Medicare billing code to support insurance coverage and payment for the testing.
Inheret CEO and Founder Dr. David F. Keren talks about the origins of the cancer risk detection platform and his mission to identify hereditary diseases early.
Mammoth Biosciences is applying CRISPR technology to both diagnostics and therapeutics. With the new financing, CEO Trevor Martin said that the company is looking ahead toward clinical trials and perhaps partnerships with larger companies.
The San Diego-based company began marketing its first product, a portable Covid-19 test, after receiving an emergency use authorization last year. Now, it’s filing the initial paperwork to go public as it scales up manufacturing.
The Knowledge Hub from MedCity News is designed to help you get targeted healthcare leads and scale your business, at no upfront cost to you.
The clock is ticking down for payers and providers to comply with the No Surprises Act, which protects patients from balance billing for the most common ancillary medical services. Here’s how to get your ducks in a row.
MedCity News has launched the Knowledge Hub to help you get targeted healthcare leads and scale your business, at no upfront cost to you.
In closing its Grail acquisition before U.S. and European regulators sign off, Illumina is taking a chance the deal will pass regulatory muster. It’s a potentially pricey gambit, as Illumina could face fines for its early action and there are no assurances that regulators will agree that the deal is not anticompetitive.
At the intersection of health tech and diagnostics, hc1’s CEO Brad Bostic talked about the company’s origins and how it works with medical laboratories, hospitals and health plans.
GS Labs, a Covid-19 testing provider, has submitted over $9.2 million in claims to the insurer as a result of its grossly inflated prices, the lawsuit states. The testing company rejected the claims, saying its “prices accurately reflect the level of service” it provides.
The Federal Trade Commission and the European Union are reviewing the soundness of this acquisition. But if Illumina acquires Grail, the company that it spawned back in January 2016, will it squeeze the nascent liquid biopsy market?
To date, AI has demonstrated value in its ability to handle asynchronous tasks such as image triage and detection. What’s even more interesting is the potential to enhance real-time image interpretation by giving the computer context that lets it work with radiologists instead of trying to replace them.
DNA sequencing company Pacific Biosciences has reached a $600 million agreement to acquire Omniome, a startup with complementary sequencing technology. The cash and stock deal comes about 18 months after antitrust concerns led PacBio and sequencing giant Illumina to terminate their tie-up.
Read about new developments from HealthMine, TailorMed, Heru and Entos.
Biological Dynamics CEO Raj Krishnan and CFO Kevin Han shared what informs their vision for developing liquid biopsies to detect cancer at the earliest stages to ensure the best outcome for patients.
A diagnostic test to detect long COVID could be available within six to 12 months, following the discovery that patients with the chronic condition have distinctive antibodies in their blood. Researchers at Imperial College London (ICL) led by Professor Danny Altmann told the BBC’s Panorama programme that they have identified a pattern of antibodies in […]
Xilis is developing technology that creates a living model of a patient’s tumor, then applies artificial intelligence to determine the best drug or drug combinations to treat the cancer. Clinical trials are planned to test this precision medicine approach and the biotech startup has raised $70 million to fund its research.
Stand Up To Cancer and Exact Sciences are teaming up to increase colorectal cancer screening awareness and research such that people don’t have to die from this preventable disease.
Experts in precision medicine provide a broad overview of where we are and where we need to go to make the promise and potential of this sector a reality.
This panel explores some of the diverse approaches companies are taking to improve efficiency and avert pitfalls in therapeutic development.
Video from the Health IT and Life Science tracks of our Pitch Perfect contest at INVEST Precision Medicine is now available to view.
The INVEST Precision Medicine conference cast a spotlight on the role of children’s hospitals, biopharma companies, diagnostic companies and startups in biopharma innovation. The video recordings of the conference sessions are now available to view.
In a wide-ranging interview, Dr. Geoff Vince, the new executive director of Cleveland Clinic Innovations, discussed his plans for how the commercialization arm will operate, the technologies he thinks will drive interest and whether the pandemic has changed approaches to innovation.
On the final day of INVEST Precision Medicine, a panel with Caris Health, CVS Health, and Intermountain Healthcare will share assessments of precision medicine’s progress and the outlook for this sector. Also, a panel will highlight non dilutive funding opportunities for startups. Register now!
Advances in the field of biotechnology have enabled the development of several minimally invasive / non-invasive approaches for diagnosis of fibrotic diseases which include imaging diagnostics and biomarker-based assays. Among the biomarker-based tests, liquid biopsy (based on the analysis of biofluids such as blood, urine and / or plasma), a relatively new concept, has emerged […]
The at-home testing startup plans to launch a broader virtual care offering after raising $150 million in funding. It plans to roll out virtual visits and offer prescription medications, in addition to building out its array of tests.
Truepill, the company operating behind-the-scenes to help digital health companies with pharmacy fulfillment and telehealth visits, has added a third feature: at home testing. CEO Umar Afridi hopes the trio of services will create a seamless experience for most people’s basic health needs.
The nation’s largest public health system will stop using clinical assessments for kidney function and vaginal delivery after C-sections that use race-based calculations for determining illness severity and risk. These assessments can result in people of color not receiving the diagnoses and treatments they need.
Cue Health, a startup that won a big government contract for its at-home Covid-19 test, recently raised $235 million in funding. The startup plans to use the funds to grow and offer additional types of tests.
Leveraging artificial intelligence can shave years off the difficult process of diagnosing a rare disease. By safely sharing patient data, more will benefit globally.
Ellume, a startup that won a $232 million contract to manufacture more of its over-the-counter Covid-19 tests in the U.S., has started building a manufacturing facility in Maryland. In the longer term, it plans to use the site to prepare for future outbreaks and pandemics.
Mayo Clinic shared results of a study showing that an AI tool developed by the system could be used to improve diagnosis of low ejection fraction, a type of heart disease. It’s part of a broader push by Mayo Clinic to commercialize AI-based diagnostic tools, starting with spinout company Anumana.
Read about news from life science companies Emulate, Astrocyte Pharmaceuticals and Bone Health Technologies.
Startups for the diagnostics field present their solutions to a panel of investor judges.
The finalists across health IT, biopharma, medical devices, diagnostics, and health services tracks were judged on criteria that included: completeness of overall plan, business idea, market opportunity, revenue model, and founder(s) experience.
The neuroQWERTY technology can analyse people’s typing for signs of motor conditions like Parkinson’s disease – and now the team behind it is looking to expand into the notoriously-difficult area of dementia. Teresa Arroyo-Gallego tells us about the science behind the technology and how the team hopes to reshape cognitive screening. While many disease areas […]
That is the topic of a recent paper by Augustovski et al. (2021). The authors conduct a targeted literature review of previous diagnostics value frameworks in other countries. A full list of these articles is below. Then the researchers pool the criteria and created a proposed value framework. A panel of experts was then met […]
As part of MedCity’s 2021 INVEST conference, Cesar de la Fuente, presidential assistant professor at the University of Pennsylvania, explains the value of the rapid low-cost diagnostic test he has developed to detect SARS-CoV-2 and how the platform technology can be deployed to detect other diseases cost-effectively.
In response to emailed questions, the CEO and CTO talk about the immune intelligence startups’ Human Immunity Map — a growing database of immune interactions that can support the development of multiplex diagnostics, vaccines and therapeutics.
After insurers were mandated to cover at-home Covid-19 tests, more people tested at-home screenings for other conditions. As preventive tests declined significantly during the pandemic, insurers also turned to creative means to give people access.
After the Food and Drug Administration authorized a swathe of over-the-counter tests for Covid-19, pharmacies are preparing to stock their shelves. But at $20 to $100 a pop, will enough people use them to make a difference?
Mayo Clinic struck joint ventures with two startups to develop and commercialize AI diagnostic tools. It’s part of a broader plan by Mayo Clinic to develop more AI tools to support clinical decisions.
Peter Meath, Co-Head of Healthcare and Life Sciences for Middle Market Commercial Banking at J.P. Morgan, is bullish that the momentum will continue, particularly with investment trends focused on pain points amplified by the Covid-19 pandemic, from diagnostics development to supply chain management.
Mobidiag offers multiplex testing, which is the ability to test for multiple pathogens from a single test sample. Hologic said the acquisition will enable the company to enter the acute care test market, which is projected to grow in a post-pandemic world.
The conference highlights the intersections of technology and life sciences through the prism of precision medicine. The topics at the conference span pediatric innovation in precision medicine, how tech companies are addressing clinical trial challenges, supply chain management, and more.
Finalists for the diagnostics track at INVEST Pitch Perfect include tests for upper respiratory infections, breast cancer screening, in vitro cellular immunoassays, dysphagia diagnostics, and neuroscience.
The Food and Drug Administration gave an emergency use authorization to two more over-the-counter Covid-19 tests that can be used without a prescription. They include Abbott’s BinaxNow test and an at-home test developed by Quidel Corp.
Peter Meath, J.P. Morgan Commercial Banking’s Co-Head of Healthcare and Life Sciences, applies lessons from 2020’s remarkable second half and shares insights on what to expect in 2021.
The Federal Trade Commission is opposing Illumina’s proposed $7.1 billion Grail acquisition, arguing that it will reduce competition for multi-cancer early detection tests. Illumina disagrees with the regulator’s position and will oppose the FTC’s challenge.
Tuberculosis is highly infectious and a global problem that Covid-19 has only made worse. Ironically, two legacies of our response to Covid-19 can give us hope. Many health systems now have unprecedentedly large testing and tracing infrastructures that we can use to test for TB.
After a busy year, at-home testing company Everlywell is growing through two acquisitions. It bought telehealth practice PWNHealth and another at-home lab testing company.
Private equity firm Accelmed recently closed an oversubscribed, $400 million fund. The firm primarily invests in health-tech startups, such as its recent investment in medication adherence company MedMinder.
VitalConnect’s CEO Peter Van Haur believes his company’s product not only does a great job in real time cardiac remote monitoring but also has something larger competitors lack: the ability to monitor other vital signs
Roche already sells a Covid-19 diagnostic. In acquiring GenMark Diagnostics for $1.8B, Roche is adding technology that can detect SARS-CoV-2 along with multiple respiratory diseases in a single test from a single patient sample—a capability the Swiss multinational company does not currently offer.
Roche has said it will pay $1.8 billion for molecular testing company GenMark, boosting the Swiss company’s diagnostic capabilities and adding rapid COVID tests to its pandemic arsenal. GenMark’s tests are designed to rapidly detect multiple pathogens from a single patient sample. Of particular interest at the moment are its Respiratory Pathogen Panels, which identify […]
As the Biden Administration pushes to offer more over-the-counter Covid-19 tests, the Food and Drug Administration authorized the first molecular Covid-19 test for over-the counter use. The test was developed by San Diego-based startup Cue Health.
Slovenski left his perch atop Walmart Health last year to join a diagnostics company that has been around since 2005. In our latest podcast episode, he talks about the future of the diagnostics industry and his ambitions for a wholesale reinvention.
Benchtop blood testing startup Truvian raised $105 million in series C funding, which it plans to use to pave the way to submit its device for FDA clearance.
As Covid-19 joins the ranks of cancer and chronic diseases to be tracked and prevented through testing, health plans will need testing solutions that can be distributed quickly and at scale.
After Everlywell received an emergency use authorization last year from the FDA for its at-home collection kit, the agency gave Everlywell the green light to sell its test kits without requiring a prescription.
Two UnitedHealthcare policies have raised several concerns among providers, including that they may display anti-competitive behavior and could block patient access to certain healthcare services. The American Hospital Association is asking the FTC and CMS to review and potentially block these policies.
Nautilus, among the biotechs developing protein analysis tools for drug discovery and diagnostics, already has a partnership with Genentech. As it prepares to go public, Nautilus aims to do for proteomics what Illumina did for genomics.
Consumer DNA testing company 23andMe plans to go public through a merger with a special-purpose acquisition company started by Virgin Group. As sales of DNA testing kits wane, how will 23andMe drum up new interest for its business?
Ellume, whose at-home Covid-19 test was cleared by the FDA in December, got a $232 million contract from the Department of Health and Human Services to deliver 8.5 million tests.
The startup pitch contest is part of our INVEST conference, April 19-23, which will be hosted online due to the Covid-19 public health crisis. It includes five tracks for startups: biopharma, medical devices, diagnostics, health IT and health services.
The INVEST Pitch Perfect contest is part of our INVEST conference April 19-23, which will be hosted online due to Covid-19, and includes five tracks for startups: biopharma, medical devices, diagnostics, health IT and health services. Read more on how to apply.
ChromaCode’s founders seek to break the paradigm of limited access to the most powerful diagnostic tools by deploying inexpensive reagent kits and software using traditional PCR detection systems so physicians can initiate testing using the most informative diagnostics without having to worry about access or cost.
Metagenomics applied in a rapid clinical setting was unthinkable just a few years ago but now can be deployed by any hospital with local deployment.
During a panel discussion at the J.P. Morgan Healthcare Conference, three physicians from Stanford Medicine discussed the investment opportunities that can help accelerate innovation in healthcare in the coming year.
The two companies are working together to detect instances of the more contagious B.1.1.7 variant in the U.S. After Colorado identified the first case in the U.S. on Dec. 28, more than 60 cases have since been found across the country.
Shots: The acquisition will integrate AmpTec’s PCR-based mRNA technology with Merck’s expertise in lipids manufacturing, providing combine offering across mRNA value chain The deal will expand Merck’s capabilities to develop & manufacture mRNA for use in vaccines, treatments, and diagnostics applicable in COVID-19 and many other diseases. Additionally, AmpTech’s diagnostic business focusing on customized long […]
In an unusual move, the Food and Drug Administration issued an alert about false negatives in startup Curative’s Covid-19 test. The test was being used by the County of Los Angeles, as well as Congress.
The company, which got started in genomic testing, has quickly expanded its services to include providing Covid-19 testing at businesses and universities. With the new funding, it plans to build infrastructure for more preventive health services.
DNA testing company 23andMe raised $82.5 million in funding, according to a recent filing. Earlier this year, decreased sales of tests kits led to cuts at the company and its competitors.
A video from the conference spotlights startup pitches and Q&A with judges in the Life Science track of the Pitch Perfect contest.
The genomic test, known as Oncotype DX, can help predict whether women with certain forms of breast cancer will benefit from chemotherapy — and those who won’t. The latest trial results extend the test’s reach.
Moderna is using a Roche antibody test in clinical trials of its Covid-19 vaccine. The test can measure the antibodies created through vaccination, offering a window into how long protection lasts.
Judges picked Amplified Sciences as the winner of the health IT track at MedCity INVEST Precision Medicine. The startup is working to combat adverse drug reactions by making pharmacogenomic testing easier to access and interpret.
Here is our attempt to capture this bewildering and memorable year by highlighting the phenomena and personalities who made it so.
Beckman Coulter said it would file for an emergency use authorization for a SARS-CoV-2 antigen test that costs only $4.
More than 80% of representatives of health systems have established genomic data management strategies or plan to do so within the next couple of years.
The FDA authorized an at-home antigen test for Covid-19 developed by Ellume. It does not require a prescription.
To help clinicians diagnose rare disease more quickly and accurately, many healthcare organizations are embracing technology solutions like natural language processing (NLP) tools that can create augmented intelligence workflows that facilitate the rapid search of unstructured clinical data from multiple data sources.
The future of precision medicine will come only as quickly as doctors can pick out clinically useful information from the genetic data being gathered on their patients.
The final day of the conference, Friday, December 11, includes a panel on precision medicine investment trends, a look at clinical trial design innovation and the life sciences track of our Pitch Perfect startup contest. Register now!
In the last 20 years, access to genetic testing has expanded significant as technology has advanced. But there’s still lots of work to be done to get tests covered and make them more accessible, panelists said at a virtual conference hosted by MedCity News.
COVID-19’s knock-on effect on cancer patients is of concern by HCPs, with delayed or decreased diagnosis seen as a key worry. CREATION.co’s Lara Meyer explores why HCPs need more support. The COVID-19 pandemic has been mainstream headline news throughout 2020 and continues to have a profound impact on all our lives. A key concern that […]
Among the areas of interest for companies presenting at Pitch Perfect at INVEST Precision Medicine are clinical stroke detection, making medical research more inclusive, using technology to accelerate the pace of clinical trials, developing more patient friendly drug delivery systems for reconstitutable drugs, and more.
Proscia and other digital-pathology firms promise to make pathologists more efficient as they analyze tissue. The need is driven by a steadily declining U.S. population of pathologists.
The Austin-based startup has distributed more than 500,000 Covid-19 test kits to date, and expects total sales to quadruple by the end of the year.
The retailer is offering at-home Covid-19 testing kits, including nasal swabs and saliva test kits, from Los Angeles-based startup myLab Box.
Unlike inherited genetic predispositions, accumulated genetic changes are the result of environmental influences, such as smoking, chemicals or ultra-violet radiation. A growing body of research links somatic changes to an increased likelihood of blood cancers and cardiovascular disease, both heart disease and stroke.
In this episode of the MedCity Pivot podcast, Daniel Levner, co-founder and chairman of the scientific advisory board at Sight Diagnostics, explains how computer vision is changing blood diagnostics.
Here’s a preview of some of the panel discussions at INVEST Precision Medicine, including diagnostics, investment trends, and building a bioinnovation hub.
The partners pooled results from two trials and two different dosing regimens, one appearing to be more effective than the other. They hope to produce 3 billion doses in 2021 with an emphasis on serving poorer countries.
The authorization comes as Covid-19 testing demand threatens to swamp U.S. labs. However, it will take time for the Lucira test to become available nationwide.
The cancer and cardiovascular care provider has teamed up with GE Healthcare, granting its 440 centers in the U.S., U.K., Spain and Australia access to GE equipment and services. The organizations will also explore research opportunities.
The company is the second this month to report promising results for a Covid-19 vaccine even as the virus rages across the U.S.
News of positive results from Pfizer’s Covid-19 vaccine is heartening but historically, important scientific announcements about vaccines are made through peer-reviewed medical research papers that have undergone extensive scrutiny about study design, results and assumptions, not through company press releases.
Check out news from healthcare startups including Truvian Sciences and Seven Bridges Genomics.
Following years of research and investment, liquid biopsies are steadily accumulating FDA approvals. The tests are being used in molecular profiling of solid tumors and as companion diagnostics for targeted cancer therapies.
In the coming years, clinicians will be presented with a larger and more capable toolbox to aid in the diagnosis of sepsis, directly overcoming the drawbacks of culture-based diagnostics.
the pandemic has brought much-needed attention to how technology can help take down barriers to care and bridge care gaps—by shifting healthcare to people’s homes.
The summit gathers directors through the C-suite from across life science and healthcare sectors to discuss new developments in precision medicine, investment trends, and how health IT, diagnostics and biopharma technology are being used to improve outcomes.
CVS Health plans to add rapid Covid-19 tests at 1,000 locations by the end of the year. The company has not specified which rapid tests it will offer.
Founded in 2017, Artidis has raised $15.1 million and hopes to enter the U.S. market for cancer diagnosis by 2022. But the startup first has to convince the FDA that its device works.
The regulatory clearance would allow AIdoc’s system to be used to detect incidental pulmonary embolism, meaning that it could flag unsuspected findings in CT scans.
Starting in January, Medicare will pay $75 for tests that take longer than two days, and will only pay $100 per test to laboratories that process most of their Covid-19 tests in less than two days.
Advancements in the field of disease diagnostics have led to development of point-of-care medical imaging devices; handheld ultrasound scanners have emerged as a novel solution to cater to unmet need in this domain. These handheld ultrasound imaging devices are the lightest portable ultrasound devices, which permit patient diagnosis from a single transducer and transmit images […]
Global healthcare funding set a new record in the third quarter, according to data from CBInsights. Healthcare companies raised a total of $21.8 billion across 1,539 deals.
Roche’s pharmaceutical revenues have been hit by falling sales in its pharma division in Q3 but a spike in demand for COVID-19 tests spared the Swiss company’s blushes. Sales of its “big three” cancer drugs were all down considerably in Q3 as cheaper biosimilars gained market share in the US. Avastin was down 30% compared […]
Google’s sister company launched a program in California and other states to help route patients to nearby coronavirus testing. Dr. Vivian Lee, president of health platforms for Verily, shared lessons learned from that effort and Verily’s work with schools and businesses.
When evaluating a new diagnostic, HTA agencies must assess two separate issues: analytical and clinical validity. Analytical validity basically indicates whether the test works; is it able to accurately predicts the presence or absence of a particular biomarker of interest. Clinical validity is whether the test matters in clinical practice. It could be the case […]
When evaluating a new diagnostic, HTA agencies must assess two separate issues: analytical and clinical validity. Analytical validity basically indicates whether the test works; is it able to accurately predicts the presence or absence of a particular biomarker of interest. Clinical validity is whether the test matters in clinical practice. It could be the case […]
San Diego-based diagnostics startup Cue Health won a $481 million from the Department of Health and Human Services and the Department of Defense to produce more coronavirus tests. The company received an emergency use authorization in June for its rapid molecular test.
Shots: The agreement leverages Imbio’s technical, regulatory & commercial expertise to build medical imaging AI technology for use in research, clinical trials & clinical practice The focus of the agreement is to develop quantitative imaging diagnostics for lung diseases and to bring unique solutions for pulmonary imaging. The collaboration integrates Imbio’s expertise in imaging biomarkers […]
Supplies of swabs for coronavirus and other critical NHS tests for diseases like cancer, diabetes and heart disease have been threatened by a failure at a facility operated by Roche. The company said the problems – which also include other items like reagents and screening kits – have resulted from a switch to a new […]
Supplies of swabs for coronavirus and other critical NHS tests for diseases like cancer, diabetes and heart disease have been threatened by a failure at a facility operated by Roche. The company said the problems – which also include other items like reagents and screening kits – have resulted from a switch to a new […]
The company announced Wednesday the FDA approval of its liquid biopsy test, the second to win an agency nod in less than a month, saying it would launch the product on Friday. The FDA acquired the first ever liquid biopsy companion diagnostic, Guardant Health’s Guardant360 CDx, on Aug. 10.
In an interview, Peter Meath, J.P. Morgan’s co-head of Healthcare and Life Sciences, Middle Market Banking & Specialized Industries, says the Covid-19 pandemic has cast a bright light on the life sciences industry with startups raising venture funding at record levels as the virus has transformed the way people usually do business in the sector.
Cambridge, UK-based Biofidelity has raised $12 million in first-round funding for its cancer diagnosis platform, which can detect mutations quicker than current approaches like gene sequencing. The Series A comes just a few months after Biofidelity launched with seed funding from Longwall Ventures and private backers – as well as multinational diagnostics company Agilent. Barnaby […]
Earlier this month, Ohio Gov. Mike DeWine received a false-positive result from a rapid antigen test for Covid-19, raising concerns about the tests’ accuracy. The assay’s maker, Quidel, said it is investigating the case.
The Chicago-based startup company plans to use the funding to further growth of its product offering and integration with EHRs and genetic testing partners.
In a phone interview, Guardant Health CEO Helmy Eltoukhy said he expected the approval to encourage coverage by those payers still on the sidelines.
MedCity News has the most engaged healthcare business audience in the industry. We can collaborate with you to develop customized content or provide a platform for your business to present sponsored thought leadership content highlighting from executives in healthcare and life sciences.
The new report, from the University of Pittsburgh Medical Center’s Center for Connected Medicine, surveyed 101 representatives of hospitals and healthcare systems. Nine out of 10 respondents said they were providing genomic or genetic testing or planning to.
With this new cash infusion, Sight Diagnostics, which uses machine learning and AI to analyze images of blood samples, has raised a total of $124 million since its inception in 2011.
Amplified Sciences emerged as the winner of the diagnostics track for the MedCity INVEST conference’s Pitch Perfect contest with PanCystPro, the test it is developing to address the problems encountered when determining whether pancreatic cysts are cancerous.
In a Q&A, Truvian Sciences CEO Jeff Hawkins and Dena Marrinucci, founder and SVP Corporate Development and Business Operations talk about their point-of care blood testing technology.
With more readers and greater engagement in our content than ever, we have many products that can help you reach your customer base through our content, ads, podcasts and online events. Contact us to learn more.
The study design is still being finalized, and the company is thus not yet divulging too many details. However, CEO David Daly said it would be significantly larger than the previous DETECT-A, multi-center and would include both men and women.
Shots: The study involved 1402 patients across 3 cohorts: a) 81 patients in Arizona (34 with AD and 47 without), b) 699 in Sweden (301 with no cognitive impairment, 178 with mild cognitive impairment, 121 with AD dementia and 99 with other neurodegenerative diseases) and c) 622 in Colombia (365 with E280A mutations and 257 […]
Tel Aviv-based Ibex Medical Analytics published data on what it called the first algorithm to go beyond detection and into areas like tumor grading and sizing.
Healthcare startups across health services, health IT, medical devices, biopharma and diagnostics tracks took part in the week-long competition at the conference July 20-24. Here are the winners for the five tracks.
Healthcare mergers decreased in the first half of 2020, but not to the extent expected as a result of the Covid-19 pandemic. Reports by Pricewaterhouse Coopers and Kaufman Hall showed a decline in mergers and acquisitions, but still reported sustained interest from buyers
Today marks the last day of INVEST. Check our events page for agenda updates for our other virtual conferences this year including INVEST Digital Health, INVEST Population Health, INVEST Precision Medicine, and our collaboration with HLTH: ENGAGE at HLTH.
The company said it was formally terminating the Phase III study of the drug elafibranor in NASH and refocus its development of the drug on another disease, primary biliary cholangitis, as well as a diagnostic for NASH.
The company said the CareStart Covid-19 MDx RT-PCR test is designed to detect RNA from the SARS-CoV-2 virus and produce results within 83 minutes.
How can companies strike the right balance between growing and scaling their business? A new report shows how an HR team can help.
In an interview, TriNet’s Vice President of Life Sciences, Maria Abouseif, talked about the role Professional Employer Organizations play in helping life science companies navigate the COVID-19 public health crisis.
Shots: UK Rapid Test Consortium’s (UK-RTC) finger prick test passes its first major trial that delivers results in 20mints. and demonstrate 98.6% accuracy in its clinical study. The AbC-19 lateral flow test is the first approved Ab test for Covid-19 in the UK that generates an instant result The clinical trial involves ~300 people and […]
Shots: The US FDA has authorized Quest SARS-CoV-2 rRT-PCR test for use with pooled samples containing up to 4 individual swab specimens collected under observation. The Quest test is the first COVID-19 diagnostic test to be authorized for use with pooled samples Quest Diagnostic expects to deploy the technique at its laboratories in Chantilly, VA […]
Pamela Aldsworth, head of VC coverage and managing director at J.P. Morgan, discusses deals and dealmaking during the pandemic and how startups can survive, in a special presentation to mark MedCity News’ annual INVEST conference.
Shots: Under the amended agreement, the offer price increased from $44.5 to $49/QIAGEN share in cash, representing a premium of 35% to the closing price of QIAGEN’s ordinary shares on the Frankfurt Prime Standard on Mar 2, 2020, making the latest deal value as $12.5B The amendment also provides for a reduction of the minimum […]
Naysayers have been proven wrong multiple times over as companies across the biotech industry have advanced to deliver diagnostics and detection assays across a number of different cancer types enabling predictive testing, early diagnosis and objective results.
The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for the disease.
Researchers in Spain, one of Europe’s worst-hit countries, randomly selected more than 61,000 people, but found that even in places with high infection rates like Madrid, relatively few people tested positive for antibodies against SARS-CoV-2.
The current pandemic, which has caused treatment delays, is simply another reason that home-based treatment options should become more readily available to cancer patients.